Key result
Song Zhi Wan administration in high-fat diet-induced obese mice reduced the proportion of mice with severe steatosis (59% vs 90% for placebo; P=0.079) and significantly reduced triglycerides.
Why the study?
Effective treatment against non-alcoholic fatty liver disease is lacking, though Song Zhi Wan has demonstrated hepatoprotective effects in chronic hepatitis C patients.
Does Song Zhi Wan (SZW) improve lipid profiles and hepatic steatosis in high-fat diet-induced obese mice?
Does Song Zhi Wan (SZW) improve lipid profiles and hepatic steatosis in high-fat diet-induced obese mice?
Absolute Event Rate: 59% vs 90%
p-value: p=0.079
Song Zhi Wan (SZW) administration attenuates hypercholesterolemia, reduces dyslipidemia, and alleviates hepatic steatosis in a high-fat diet-induced obese mouse model.
SZW attenuates dyslipidemia and steatosis in obese mice; leaves open human efficacy and requires clinical trials.
Background: Effective treatment against non-alcoholic fatty liver disease (NAFLD) is lacking. Song Zhi Wan (SZW), a Chinese formulation medicine comprising eight herbal ingredients, has been demonstrated to confer a liver protective effect in chronic hepatitis C patients. We aimed to investigate the effect of SZW on NAFLD using a high-fat diet (HFD; 60% fat) induced obese mouse model. Methods: C57BL/6J mice were fed with HFD for 10 weeks, followed by daily oral administration of various dosages of SZW (low [n=6], normal [n=10], high [n=10]) or water (n=10) for 8 weeks. Another formulation of SZW (modified SZW), in which two ingredients were replaced by radish seed and barley, was tested. Serum total cholesterol and triglyceride levels, liver transaminases, and histologic steatosis were assessed. Results: At the end of experiment, the HFD-fed placebo mice had a mean increase in serum total cholesterol and triglyceride by 57.7% and 35.0%, respectively. HFD-fed mice receiving either SZW formulation had a smaller increase in serum total cholesterol (mean increase 7.9% – 39.4%) and a significant reduction in triglyceride (mean reduction 4.2% – 27.4%; P < 0.05). A dosage dependent effect on serum total cholesterol and triglyceride was observed with modified SZW (=0.043 and 0.006, respectively). 90% of placebo mice and 59% of SZW-treated mice had severe steatosis (P=0.079). With an escalating dosage of original SZW, there was a decreasing proportion of mice with severe steatosis (P=0.013). Conclusion: SZW administration can attenuate hypercholesterolemia, reduce dyslipidemia and alleviate steatosis in HFD-induced obese mice.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2021) studied Non-alcoholic fatty liver disease (NAFLD) (n=36). Song Zhi Wan (SZW) vs. water was evaluated on Severe steatosis (p=0.079). Song Zhi Wan administration in high-fat diet-induced obese mice reduced the proportion of mice with severe steatosis (59% vs 90% for placebo; P=0.079) and significantly reduced triglycerides.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: